Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Miami
About this trial
The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care, quality of life, and financial burden.
Eligibility criteria
Qualifiers
Be diagnosed with, or have a recurrence of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN).
Be currently receiving treatment which started within the past 18 months OR
Be planning to start treatment within one month OR
Have received Bone Marrow Transplant or CAR-T cell therapy within the past 100 days.
Disqualifiers
Are not diagnosed with, or have a recurrence of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN)
Be currently receiving treatment which started within the past 18 months OR
Be planning to start treatment within one month OR
Have received Bone Marrow Transplant or CAR-T cell therapy within the past 100 days.
Trial design
Treatments tested in this trial
- LLS Program
Treatment groups
400 Participants
are divided into 2 treatment groupsLocations
3Sylvester Comprehensive Cancer Center33136, MiamiFlorida, United States
University of Chicago Comprehensive Cancer Center60637, ChicagoIllinois, United States
Mays Cancer Center at UT Health San Antonio78229, San AntonioTexas, United States
Sponsors and collaborators
University of Miami
Lead sponsor
Blood Cancer United
Collaborator
Source ClinicalTrials.gov